Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria

Drug Name

Ultomiris™ (ravulizumab-cwvz)

Developer

Alexion Pharmaceuticals

Therapy Class

Monoclonal antibody

Product Description

Complement inhibitor

Current Indication

Paroxysmal nocturnal haemoglobinuria

Market Sector

Haematology

Developmental Status

Approved in the US
Expand

Go Top